Mid-period crossings: the quarter's story is things that started during it and are still completing
The model's full reasoning — Q1 2024 call → NOThe question asks whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the period or just around its edges, and whether management makes clear that this newly started activity is still completing its climb, so the period's reported numbers averaged the 'before' and 'after' and therefore sit below the level at which the business is already running. Let me examine the transcript for evidence of both halves: (1) THE PERIOD CONTAINED REAL STARTS, NARRATED AS STARTS. Management describes one or more concrete pieces of business that genuinely BEGAN during or immediately around the reported period. Looking at the transcript, what starts are mentioned? - The PRESERVE study enrolled and treated its final patient during the first quarter. This is a study completion, not a business start. - The APEX PE study is now more than 75% enrolled. This is ongoing, not a start. - Auryon platform grew 26% year-over-year. This is established business performing well. - NanoKnife grew 36%. Established business. - Mechanical thrombectomy declined 6%. Established business. - AngioVac received breakthrough designation. This is a designation, not a business start. - The company is holding its fourth Scientific Symposium at the end of October. This is future, not in the period. What about the divested businesses? The Dialysis and BioSentry businesses were divested in mid-June. That's a divestiture, not a start. The company mentions "we recently received a breakthrough designation for the use of AngioVac to remove right heart vegetation" - this is a designation, not a business start. The company mentions "we anticipate receiving CE Mark for Auryon in the next few months" - this is future, not yet happened. The company mentions "we intend to launch catheters specially designed to allow Auryon to treat small vessel DVT in 2025" - this is future. The company mentions "we are also pursuing plans to gain an indication for Auryon to treat coronary artery disease" - this is future. So what actually STARTED during the period? The PRESERVE study completed enrollment (final patient treated). The APEX PE study is 75% enrolled. These are clinical studies, not business activity generating revenue.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
AFL · Q2 2023 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the Japan Post cancer insurance launch in early April, which began selling the product and drove a 60% sales increase as a major contributor. They describe the activity as real and transacting, with Dan Amos noting the significant contribution from the new product. Yoshizumi confirms gradual increase going forward, and Fred highlights runway for more agents and sales calming down after initial jump, indicating the Q2 numbers reflect partial ramp-up rather than full run-rate.
ESE · Q2 2016 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the real mid-period start of Plastique's contribution (acquired partway through Q2, with two months of performance noted and "early performance consistent with our acquisition forecast"), treated as a key new segment. It also explicitly addresses the incomplete climb, noting that the reported Q 2 numbers lag due to partial contribution and that Q3/Q4 will see fuller periods plus seasonality, with the business already running at a higher level as the ramp continues.
PSX · Q4 2016 → YESThe question is about whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the per...YES The transcript shows management centering the Q4 story on the Freeport LPG Export Terminal's real start: commissioning completed smoothly, first commercial cargo shipped mid-December (partial Q4 contribution), with full-quarter costs incurred but only partial revenue, and explicit ramp to near-capacity loading in January onward.